Kornimate/medical-research-clean huggingface dataset:
the role of oxytocin in the second stage of labor

Conditions: Labor Complication

Summary: this is a randomized controlled trial investigating the utility of oxytocin administration in the second stage of labor.

oxytocin is widely used on labor and delivery units throughout the world.laboring patients are most likely to initiate oxytocin in the first stage of labor. among those who receive oxytocin, first stage initiation is far more common than second stage initiation. the goal of first stage administration is to increase uterine contractility and cause cervical dilation, particularly in patients who have epidural analgesia. once complete cervical dilation has been achieved, most providers choose to continue oxytocin in the second stage of labor for the theoretic benefit of increased expulsion "power" while pushing. this practice is currently not evidence-based as the limited data thus far suggests no difference in operative deliveries with the use of oxytocin augmentation in general. the benefits and risk of oxytocin continuation in the second stage of labor is unknown. oxytocin administration is associated with the risk of uterine tachysystole, postpartum hemorrhage,and maternal hyponatremia. these risks call for a closer look at prolonged oxytocin use past the first stage of labor. this is a randomized controlled trial investigating the utility of oxytocin administration in the second stage of labor.

Eligibility criteria:
inclusion criteria: * nulliparous pregnant women \>/= 37 weeks gestation * singleton pregnancies * admission for induction of labor or spontaneous labor exclusion criteria: * multiple gestations * multiparous patients * patients with major fetal anomalies * not on oxytocin at the time of complete cervical dilation * patients with fetal head visible at the perineum on diagnosis of complete cervical dilation * maternal medical condition that prohibits prolonged second stage
estrogen diastolic heart failure

Conditions: Menopause

Summary: peri-menopausal women will be randomized to hormone replacement therapy or placebo for 12 weeks to determine if markers of systolic and diastolic function change by echocardiography as well as laboratory markers of heart failure, including b-type natriuretic peptide (bnp).

this preliminary, feasibility study will randomize 28 peri-menopausal women to either hormone replacement therapy or placebo for 12 weeks. prior to randomization, each participant will undergo echocardiography, measurements of activity using the duke activity status index, measurements of quality of life and laboratory data, including b-type natriuretic peptide (bnp) measurements. following the intervention for 12 weeks, these measurements will all be repeated.

Eligibility criteria:
inclusion criteria: * 28 healthy recently postmenopausal women with last menstrual bleeding 12 months at study entry. women with last menstrual bleeding within 12 months at study entry are those who are peri-menopausal and for whom the drug is fda approved. exclusion criteria: * history of hysterectomy, oophorectomy or both * history of heart disease including cardiac transplantation, heart failure, bypass surgery or percutaneous intervention, and valve disease defined as moderate or severe valve regurgitation or stenosis * history of bone disease including non-traumatic vertebral fractures on radiography * uncontrolled chronic disease (including uncontrolled diabetes defined as a hemoglobin a1c \>8, uncontrolled hypertension defined as a systolic blood pressure \>160 mmhg, awaiting organ transplant) * previous or current cancer, excluding basal cell carcinoma * previous or current thromboembolic disease * previous intolerance of hormone replacement therapy (hrt) or oral contraception (oc) * current or previous use of hrt within the past 3 months * current or recent (\<12 months) substance abuse, including tobacco use * no drug interactions with hrt * no racial or ethnic groups will be excluded
comparison between tof and swan sequences in the detection of arterial occlusion in acute ischemic stroke using mri

Conditions: Stroke, Acute; Angiography; Magnetic Resonance Imaging; Diagnosis

Summary: optimizing the mri protocol in acute ischemic stroke remains a challenging issue. in this field, susceptibility-weighted sequences have proved their superiority over t2. besides the strengthened susceptibility effect, enhanced susceptibility-weighted angiography (eswan) sequence provides also a time-of-flight (tof) effect, allowing the exploration of the intracranial arterial circulation. the objective of this study is to compare eswan and 3d tof, considered as the reference, in the detection of arterial occlusion in acute stroke.

patients who undergo mri for suspected acute stroke with an acute ischemic lesion on diffusion-weighted imaging (dwi) will be prospectively included in this study.eswan and tof images will be analyzed under double-blind conditions by a junior radiologist and a senior neuroradiologist for the detection of arterial occlusion. eswan images will be assessed in order to estimate the inter-observer agreement. after a consensus, eswan and tof data will be compared to calculate inter-modality agreement.

Eligibility criteria:
inclusion criteria: * clinical symptoms compatible with acute stroke; * time range between symptoms and magnetic resonance imaging less than 4 h 30 * presence of at least one acute ischemic lesion on the diffusion-weighted images (dwi). exclusion criteria: * mr contraindications; * negative dwi; * differential diagnosis; * incomplete acquisition of the full magnetic resonance imaging protocol or technical issues leading to uninterpretable eswan and/or tof sequences (e.g.motion artifacts).

Keywords: acute stroke susceptibility-weighted imaging arterial occlusion time of flight
european cml blast crisis register

Conditions: Chronic Myeloid Leukemia in Myeloid Blast Crisis

Summary: multicentric prospective and retrospective register collecting patient with cml blast crisis diagnosed in germany and europe

since the advent of treatment with tyrosine kinase inhibitors (tki), the incidence of blast crises has significantly decreased. nevertheless, about 5% of patients diagnosed with chronic myeloid leukemia (cml) will evolve into a blast phase at some point during the course of their disease. furthermore, despite the advances made in cml treatment, outcome of patients with blast crises are still dismal. due to the rarity of this condition clinical trials are challenging, and collaboration between researchers both at national and international level is needed to collect a meaningful number of data.

Eligibility criteria:
inclusion criteria: * age \>18 years * diagnosis of bcr-abl positive cml blast crisis according to the who criteria: * blasts 20% or more of peripheral blood white cells or bone marrow cells or * extramedullary blast proliferation or * large foci or clusters of blasts in bone marrow biopsy exclusion criteria: * lack of informed consent
feasibility study of biobehavioral stress reduction intervention in patients with triple negative breast cancer

Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Negative Breast Carcinoma; Triple-Negative Breast Carcinoma

Summary: this clinical trial aims to see if patients with triple negative breast cancer can complete a biobehavioral stress reduction program that also addresses health related social needs (e.g., utilities, transportation, etc.). the stress reduction program is over ten weeks and includes stress reduction (e.g., progressive muscle relaxation), coping, problem solving, communication, and social support. health related social needs will be evaluated at the beginning of the study, and referrals will be made to social work to help address those needs. the study will examine stress as reported by the patients and also use biological markers.

primary objectives: i acceptability of the biobehavioral intervention will be determined using the client satisfaction questionnaire (csq). csq is an 8-item self-report measure with item assessing different aspects of treatment satisfaction (e.g., quality of service, the degree to which needs were met, overall satisfaction). iii tolerability of the biobehavioral intervention will be assessed by analyzing pre to post treatment change on the profile of mood states. iii feasibility of the biobehavioral intervention will be assessed using three metrics: 1) accrual number as a percentage of available patients approached; 2) number/percent of patients completing each bbi session; and, 3) number/percent of patients retained and completing 10 bbi sessions. secondary objective: i. to examine the feasibility of collecting biomarkers--white blood cell count, c-reactive protein, interleukin-6, tnf-alpha (α), systolic blood pressure, diastolic blood pressure, heart rate, total cholesterol, high-density lipoprotein; albumin, hemoglobin a1c, body mass index (bmi). exploratory objective: i. to test for pre/post effects of the biobehavioral stress reduction intervention on measures of stress (impact of events scale), mood and psychological symptoms, and allostatic load. outline: patients receive biobehavioral stress reduction intervention while on study. patients undergo blood specimen collection at baseline and follow up, and have their medical records reviewed.

Eligibility criteria:
inclusion criteria: * age \>=18 years * untreated newly diagnosed triple negative breast cancer * stages i-iii exclusion criteria: * prisoners * male * identifying as american indian, alaska native, asian, native hawaiian or other pacific islander * individuals not able to speak and understand english * known personal history of ductal carcinoma in situ (dcis) or invasive breast cancer * stage iv breast cancer
cerebrovascular autoregulation during and after liver transplantation

Conditions: Encephalopathy, Hepatic; Cerebrovascular Disorders; Liver Failure

Summary: the cerebrovascular autoregulation (ar) is impaired in patients with hepatic encephalopathy. patients with the indication to liver transplantation mostly have mild to severe hepatic encephalopathy. transplantation should recover the encephalopathy. the aim of the study is to investigate the ar during liver transplantation, with the questions if the ar is impaired at the beginning of surgery and if there are changes in ar. for follow up the ar will be measured at the first days after transplantation at the icu.

the cerebrovascular autoregulation (ar) will be measured using transcranial doppler and calculating the index of autoregulation mx. this measurement is continuous with online calculation. so, the possible changes over the whole time of surgery can be detected. furthermore, the measurement of ar at the icu will be performed daily at the same time over a measurement period of 60 minutes and the time course of ar after liver transplantation will be described.

Eligibility criteria:
inclusion criteria: * liver transplantation * age \> 18 years exclusion criteria: * sepsis * preexisting cerebral diseases * traumatic brain injury * pregnancy

Keywords: encephalopathy, hepatic autoregulation, cerebrovascular liver failure liver transplantation
diagnostic survey of mental and substance use disorders among norwegian college and university students

Conditions: Mental Disorders; Substance Use Disorders; Treatment; Participation

Summary: the aims of this observational survey are to 1) collect data on the prevalence of mental and substance use disorders, and 2) investigate risk factors and consequences of mental and substance use disorder

this project focuses on mental health, quality of life and alcohol and substance use in students pursuing higher education. the targeted population, all norwegian college and university students, are in an important and vulnerable period of life transitions. the overall aim of the current project is two-fold: first, the investigators will conduct a clinical assessment of mental disorders by using the newly developed electronic version of the world health organization (who) composite international diagnostic interview, fifth version (cidi 5.0), developed for the who world mental health surveys. cidi 5.0 is a standardized interview assessing 30-days,12 months and lifetime prevalence for several mental and substance use disorders according to diagnostic criteria in the diagnostic and statistical manual of mental disorders 5th edition (dsm-5) and international classification of diseases 10th edition (icd-10). the overall aim of this will be to obtain accurate prevalence rates of disorders, as well as to validate and compare the briefer instrument used in the students' health and wellbeing study (shot), including the hopkins symptom checklist-25 (hscl-25). second, the investigators will examine risk factors based on data from the shot, which is one of the world's largest epidemiological studies of student health.

Eligibility criteria:
inclusion criteria: * being a fulltime college or university student * norwegian citizenship * ages 18-35 years * sufficient understanding of norwegian or english to conduct the interview exclusion criteria: * none
stratagraft safety, tolerability and efficacy in pediatric subjects

Conditions: Skin Wound; Burns; Trauma-related Wound

Summary: autografting is a surgical procedure to transplant healthy skin (donor skin) from another part of the participant's own body (donor site) to the burned part. autografting is the usual treatment for dpt burns. it works to close the wound, but can cause other problems: * donor sites are painful, can become infected or scarred, or can even become full thickness (ft) wounds themselves * treatment problems can require more grafting * additional surgery increases the risk of medical problems caused by the treatment stratatech is trying to find a safe and effective alternative to autografting to promote the healing of severe burns. the purpose of this study was to evaluate whether stratagraft treatment eliminates or reduces the need for autografting and promotes wound closure in a pediatric population with thermal burns that contain intact dermal elements and for which autografting is clinically indicated (dpt burns). participants were enrolled into one of two age-based cohorts: 2 to \< 12 years and 12 to ≤ 17 years to receive a single application of stratagraft, in up to 3 non-contiguous dpt burn areas located on the same extremity or plane of the torso.


Eligibility criteria:
inclusion criteria: * written informed consent provided by the parent(s) or legal guardian(s) and assent from the child when appropriate * have enough healthy skin to reserve as donor site(s), in case autografting becomes necessary * thermal burns of no more than a total of 30% tbsa * study treatment sites that are dpt in depth and which are clinically indicated for excision and autografting, and located on the torso or extremities * study treatment area(s) totaling 0.5% to 10% tbsa and may be composed of up to 3 non-contiguous areas located on the same extremity or plane of the torso * sufficient healthy skin available and reserved as a donor site in the event that the stratagraft treatment site requires autografting exclusion criteria: * is pregnant or breastfeeding * receiving treatment to suppress the immune system and/or systemic corticosteroids (inhaled corticosteroids are permitted) * a known history of malignancy * pre-admission insulin-dependent diabetes * concurrent trauma, conditions, and/or personal situations that, in the opinion of the investigator, may compromise the participant's safety or the study objectives * a burn injury that occurred ≥ 14 days prior to planned stratagraft application is expected to survive less than 12 months * is participating in another interventional trial, or did within 90 days before enrollment * a proposed study treatment site that has been previously excised or autografted; located adjacent to an undebrided/unexcised burn area; demonstrates signs and symptoms of wound infection, per judgement of the clinical investigator; lies across joints or is located on the feet (i.e., distal to the malleolus), hands (distal to the wrist), face, neck, buttocks, perineum, or genitalia
mri on persons with mutations in pomt2 gene (lgmd2n)

Conditions: Limb-girdle Muscular Dystrophy

Summary: pomt2 mutation is known to cause walker warburg syndrome and muscle-brain-eye syndrome. recently it has been connected to limb girdle muscular dystrophy (lgmd), a disorder characterized by muscle weakness and atrophy of the proximal muscles of the shoulder and pelvic girdles. lgmd is classified based on its inheritance pattern and genetic cause into more than 31 different types. lgmd with pomt2 mutations is a new phenotype - type 2n. very few patients with the lgmd2n phenotype has been reported. in this study, the investigators examine five new cases with the lgmd phenotype. the primary aim is to examine the muscle involvement using mri.


Eligibility criteria:
inclusion criteria: * persons with genetically verified mutations in pomt2 exclusion criteria: * all contraindications for undergoing an mri scan

Keywords: mri lgmd pomt2
evaluation of the deep tms h-coil in the treatment of major depression- augmentation of antidepressant medication

Conditions: Major Depression

Summary: evaluation of the novel deep tms h-coil design as an augmentation measure in the treatment of medication resistant major depression. stimulation is administered with and without cognitive-emotional provocation.


Eligibility criteria:
inclusion criteria: * patients diagnosed as suffering from treatment resistant major depression * right laterality exclusion criteria: * other major axis i diagnosis * severe axis ii diagnosis * risk factors to convulsions * history of drug abuse in the past year

Keywords: tms drug resistant depression
uthealth turner syndrome research registry

Conditions: Turner Syndrome

Summary: the investigators will conduct genetic comparisons between turner syndrome (ts) patients with and without bicuspid aortic valve (bav) to identify causative agents of bav in people with ts. the investigators will correlate the patterns and prevalence of structural heart defects in ts women with emerging molecular data to identify patients who are at high risk for cardiovascular complications

turner syndrome (ts) is a common chromosomal disorder that affects approximately 1 in 2500 live female births. complete or partial monosomy of one of the x chromosomes in a female is associated with various congenital heart defects (chds), which include aortic dilatation, coarctation of aorta and bav. congenital cardiovascular defects related to chd are the leading cause of death in women with ts. the turner syndrome network registry (trn registry) and genetic sample repository can address gaps in knowledge of chd in ts by facilitating the recognition of demographic and genetic patterns. trn registry-based research can improve surveillance of ts patients who are at risk for chd and provide valuable insight into genetic components of chd. the investigators will recruit ts patients into the trn registry and obtain blood and/or saliva samples after informed consent. the genetic diagnosis of ts will be confirmed using chromosomal microarrays. the array data will be also be used to identify genomic copy number variants, and rare variants in protein coding genes will be determined by exome sequencing. the investigators will derive induced pluripotent stem cells from some participants to determine why chd is so prevalent in ts. chd risk genes will be identified in comparisons between ts cases with and without congenital heart defects. to facilitate these comparisons, the investigators will abstract the demographic and medical data of registry participants from questionnaires and medical records. imaging will be used to confirm the diagnosis of chd and to determine the prevalence and severity of additional cardiovascular defects.

Eligibility criteria:
inclusion criteria: * diagnosis of turner syndrome exclusion criteria: * diagnosis excluding turner syndrome
turkish version of the lower limb assessment score

Conditions: Hypermobility, Joint

Summary: hypermobility is more than normal joint laxity, mobility, and range of motion. it is characterized by increased laxity and fragility of connective tissues. symptoms from hypermobility can begin at any age and affect women more than men. people are at higher risk than other people. it is stated that hypermobility is an important factor in orthopedic injuries and diseases. individuals with hypermobility have more frequent orthopedic complaints and the problems are usually idiopathic and chronic. studies have reported that proprioception and musculoskeletal reflex function may be affected independently of symptoms in hypermobile individuals. therefore, evaluating hypermobility is very important in preventing hypermobility-related problems and injuries and developing appropriate treatment methods. although the beighton score is the most commonly used scoring method to determine hypermobility, it may be insufficient to determine hypermobility of the lower extremities. the lower limb assessment score (llas) has been reported to be one of the most appropriate scoring methods for assessing lower extremity hypermobility in the literature. the aim of this study is to adapt llas to turkish and measure its validity and reliability.


Eligibility criteria:
inclusion criteria: * healthy volunteers * aged between 18 to 35 exclusion criteria: * using assistive devices or orthoses for the upper extremity * surgery history of the upper extremity * pain located on the upper extremity in the last 6 months * previous trauma that might restrict normal range of motion. * having degenerative or inflamatuar disease
camelia sinensis for basal metabolism and body composition

Conditions: Postmenopausal Disorder

Summary: camellia sinensis leaf extract contributes to increasing energy expenditure and calorie consumption by increasing thermogenesis. the purpose of this study is to evaluate the efficacy of camellia sinensis on basal metabolism and body composition in overweight women or with obesity in postmenopause.


Eligibility criteria:
inclusion criteria: * postmenopause * overweight or obesity class i-ii (body mass index 25-39,9 kg/m2) exclusion criteria: * changes in heart rhythm * intolerance or allergy to components * obesity class iii (body mass index \> 40 kg/m2)